Quick Answer
Crinetics Pharmaceuticals, Inc. reported Net Income Loss of -$465.32 million for the year ending 2025.
- Crinetics Pharmaceuticals, Inc. showed a decrease of -55.9% in Net Income Loss from 2024 to 2025.
- This data is from Crinetics Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), Crinetics Pharmaceuticals, Inc.'s Net Income Loss has declined by 7,630.8%.
- Historical annual values: Fiscal year 2025: -$465.32 million | Fiscal year 2024: -$298.41 million | Fiscal year 2023: -$214.53 million | Fiscal year 2022: -$163.92 million | Fiscal year 2021: -$107.64 million | Fiscal year 2020: -$73.81 million | Fiscal year 2019: -$50.42 million | Fiscal year 2018: -$27.12 million | Fiscal year 2017: -$9.16 million | Fiscal year 2016: -$6.02 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: